Addressing Quality And Regulatory Concerns Ahead Of Pre-Approval Inspections
Source: Lonza
Andreas Wirth, Vice President, Global Head of Quality, Cell & Gene Technologies and Personalized Medicine, and Christoph Meyer, Senior Director, Global Head of Quality Control, Cell & Gene Technologies, spoke about the strategies to meet the quality & regulatory requirements of cell & gene therapies (CGT), and Lonza's New Product Introduction process (NPI) for CGT manufacturing – how to identify issues early on, reduce quality & compliance risks, and how to avoid delays and rework.
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
This website uses cookies to ensure you get the best experience on our website. Learn more